97 Improving outcomes for palliative lung cancer patients: experience of a multiprofessional parallel clinic model in a district general hospital

Lung Cancer ◽  
2012 ◽  
Vol 75 ◽  
pp. S32 ◽  
Author(s):  
J. Smith ◽  
I. Williamson ◽  
A. Ionescu ◽  
A. Brewster ◽  
H. Howison ◽  
...  
2015 ◽  
Vol 13 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Cinthia Leite Frizzera Borges Bognar ◽  
Sergio Daniel Simon ◽  
Rene Claudio Gansl ◽  
Roberto Abramoff ◽  
Marcelo Aisen ◽  
...  

ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature. Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference. Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.


2020 ◽  
Vol 16 (1) ◽  
pp. 25
Author(s):  
Haryati Haryati ◽  
Holly Diany

Abstract: Lung cancer is the leading cause of malignancy in the world reaching up to 13% of all cancer diagnoses. Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR), are promising markers of inflammatory prognosis, clinical decisions for proper management of lung cancer patients. The research used a retrospective analytic observational study as its research method. Samples were taken from Pathology Anatomy Laboratory, and the medical record data of lung cancer patients in Ulin General Hospital Banjarmasin from 2017 to 2018. Male lung cancer patients have percentage of 72% with PLR NLR values by sex are not much different p>0.05. 23% of patients were aged ≥ 65 years and 77% were aged £ 65 years with value p>0.05. Adenocarcinoma reaches 65% with p>0.05. Most metastases are 44% pleural effusion with value p>0.05. Percentage of advanced stage is 90% with a higher PLR NLR value at the end stage. There is a meaningful relationship of NLR with lung cancer stage p<0.05, but no relantionship with PLR p>0.05. PRL and NRL are increased at advanced stage. NRL and PRL did not differ significantly based on age, sex and histology of lung cancer. Keywords: Platelet-to-lympho­cyte ratio (PLR), Neutrophil-to-lymphocyte ratio (NLR), lung cancer


2017 ◽  
Vol 28 ◽  
pp. v36
Author(s):  
P. Taniere ◽  
P. Taniere ◽  
M. Smith ◽  
B. O'Sullivan ◽  
F. Hughes ◽  
...  

2020 ◽  
Vol 54 (7) ◽  
pp. 535-540 ◽  
Author(s):  
Timothy J Williamson ◽  
Diana M Kwon ◽  
Kristen E Riley ◽  
Megan J Shen ◽  
Heidi A Hamann ◽  
...  

Abstract Background Lung cancer patients commonly report stigma, often attributing it to the well-established association of smoking as the leading preventable cause. Theory and research suggest that patients’ smoking history may differentiate patients’ experience of lung cancer stigma. However, there is inconsistent evidence whether lung cancer stigma varies by patients’ smoking history, owing to limitations in the literature. Purpose This study examined differences in lung cancer patients’ reported experience of lung cancer stigma by smoking history. Method Participants (N = 266, 63.9% female) were men and women with lung cancer who completed a validated, multidimensional questionnaire measuring lung cancer stigma. Multivariable regression models characterized relationships between smoking history (currently, formerly, and never smoked) and lung cancer stigma, controlling for psychological and sociodemographic covariates. Results Participants who currently smoked reported significantly higher total, internalized, and perceived lung cancer stigma compared to those who formerly or never smoked (all p &lt; .05). Participants who formerly smoked reported significantly higher total and internalized stigma compared to those who never smoked (p &lt; .001). Participants reported similar levels of constrained disclosure, regardless of smoking history (p = .630). Conclusions Total, internalized, and perceived stigma vary meaningfully by lung cancer patients’ smoking history. Patients who smoke at diagnosis are at risk for experiencing high levels of stigma and could benefit from psychosocial support. Regardless of smoking history, patients reported similar levels of discomfort in sharing information about their lung cancer diagnosis with others. Future studies should test relationships between health-related stigma and associated health behaviors in other stigmatized groups.


Sign in / Sign up

Export Citation Format

Share Document